Why the study?
Diagnosing cancer-associated stroke can be challenging, particularly when occult malignancy is not detected by standard evaluations.
Does FDG-PET/CT identify underlying cancer in patients with anticoagulation-resistant recurrent cryptogenic stroke?
Does FDG-PET/CT identify underlying cancer in patients with anticoagulation-resistant recurrent cryptogenic stroke?
FDG-PET/CT may be a valuable imaging modality for identifying occult malignancy in patients with anticoagulation-resistant recurrent cryptogenic stroke when standard evaluations are inconclusive.
May support FDG-PET/CT in select refractory cryptogenic strokes; hypothesis-generating and requires prospective validation before adoption.
The diagnosis of cancer-associated stroke can be challenging, particularly when occult malignancy is not detected by standard evaluations. We report two patients with anticoagulation-resistant recurrent cryptogenic stroke in whom FDG-PET/CT successfully identified the underlying cancer after conventional tests were inconclusive. These cases highlight the value of FDG-PET/CT in uncovering malignancy-related stroke mechanisms and emphasize its role the timely diagnosis of cancer and targeted treatment in patients with cryptogenic stroke, as well as features suggestive of occult malignancy.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: